ST-246 400 mg + ST-246 600 mg + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Orthopoxviral Disease
Conditions
Orthopoxviral Disease
Trial Timeline
Jun 1, 2009 → Jan 1, 2010
NCT ID
NCT00907803About ST-246 400 mg + ST-246 600 mg + Placebo
ST-246 400 mg + ST-246 600 mg + Placebo is a phase 2 stage product being developed by SIGA Technologies for Orthopoxviral Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00907803. Target conditions include Orthopoxviral Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00907803 | Phase 2 | Completed |
Competing Products
1 competing product in Orthopoxviral Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ST-246 Days 1 - 3 + ST-246 Days 11 - 13 | SIGA Technologies | Phase 1 | 25 |
Other Products from SIGA Technologies
Tecovirimat + sevelamer carbonate oral tablet + sucroferric oxyhydroxide chewable tablet + calcium acetate oral tablet + Lanthanum Carbonate Chewable TabletApproved
77
TpoxxApproved
77
Tecovirimat Oral Capsule + Placebo for Tecovirimat + Tecovirimat Oral Capsule (Open Label)Phase 3
69
tecovirimatPhase 3
69
TPOXXPhase 3
69